Prostatic angiogenic responses in late life: Antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model

Aging is considered one of the main predisposing factors for the development of prostate malignancies. Angiogenesis is fundamental for tumor growth and its inhibition represents a promising therapeutic approach in cancer treatment. Thus, we sought to determine angiogenic responses and the effects of antiangiogenic therapy in the mouse prostate during late life, comparing these findings with the prostatic microenvironment in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model.

[1]  V. Cagnon,et al.  Prostatic microenvironment in senescence: fibroblastic growth factors × hormonal imbalance , 2014, Histochemistry and Cell Biology.

[2]  P. Paoli,et al.  Tumor microenvironment and metabolism in prostate cancer. , 2014, Seminars in oncology.

[3]  V. Cagnon,et al.  Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice , 2014, Histochemistry and Cell Biology.

[4]  V. Cagnon,et al.  Angiogenic and Tissue Remodeling Factors in the Prostate of Elderly Rats Submitted to Hormonal Replacement , 2013, Anatomical record.

[5]  D. Mukherji,et al.  Angiogenesis and anti-angiogenic therapy in prostate cancer. , 2013, Critical reviews in oncology/hematology.

[6]  Yong Luo,et al.  Epithelial-mesenchymal transition and migration of prostate cancer stem cells is driven by cancer-associated fibroblasts in an HIF-1α/β-catenin-dependent pathway , 2013, Molecules and cells.

[7]  Shafiq A. Khan,et al.  Vascular endothelial growth factor A, secreted in response to transforming growth factor-β1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells. , 2012, Asian journal of andrology.

[8]  T. Helleday,et al.  Castration therapy of prostate cancer results in downregulation of HIF-1α levels. , 2012, International journal of radiation oncology, biology, physics.

[9]  V. Montecinos,et al.  Primary Xenografts of Human Prostate Tissue as a Model to Study Angiogenesis Induced by Reactive Stroma , 2012, PloS one.

[10]  W. Fávaro,et al.  Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion molecules. , 2011, Micron.

[11]  M. Salto‐Tellez,et al.  Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. , 2010, Endocrine-related cancer.

[12]  Peter S. Nelson,et al.  The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment , 2010, PloS one.

[13]  Jeffrey E. Green,et al.  VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. , 2010, Experimental cell research.

[14]  Yong Li,et al.  Angiogenesis as a strategic target for prostate cancer therapy , 2010, Medicinal research reviews.

[15]  S. Ponnazhagan,et al.  Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status , 2009, The Prostate.

[16]  G. Gonzales,et al.  Antagonistic effect of Lepidium meyenii (red maca) on prostatic hyperplasia in adult mice , 2008, Andrologia.

[17]  C. Stief,et al.  High level of endostatin in epididymal epithelium: protection against primary malignancies in this organ? , 2008, Histochemistry and Cell Biology.

[18]  M. Reed,et al.  Extracellular influences on tumour angiogenesis in the aged host , 2008, British Journal of Cancer.

[19]  P. Nelson,et al.  Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis , 2008, British Journal of Cancer.

[20]  A. Bergh,et al.  Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1alpha. , 2007, The Journal of endocrinology.

[21]  I. Eltoum,et al.  Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. , 2007, Cancer research.

[22]  S. Amir,et al.  Hypoxia-inducible factor (HIF) in human tumorigenesis. , 2007, Histology and histopathology.

[23]  M. Reed,et al.  The effects of aging on tumor growth and angiogenesis are tumor‐cell dependent , 2007, International journal of cancer.

[24]  D. He,et al.  Over‐expression of hypoxia‐inducible factor‐1α increases the invasive potency of LNCaP cells in vitro , 2006 .

[25]  J. Campisi,et al.  Secretion of Vascular Endothelial Growth Factor by Primary Human Fibroblasts at Senescence* , 2006, Journal of Biological Chemistry.

[26]  J. Simons,et al.  Hypoxia-inducible factor-1 in human breast and prostate cancer. , 2006, Endocrine-related cancer.

[27]  D. He,et al.  [Over-expression of Hypoxia-inducible factor 1alpha increases invasive potency of LNCaP cells in vitro]. , 2006, Zhonghua yi xue za zhi.

[28]  D. Spandidos,et al.  Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. , 2006, International journal of oncology.

[29]  A. Berghaus,et al.  Antiangiogenic combination tumor therapy blocking αv‐integrins and VEGF‐receptor‐2 increases therapeutic effects in vivo , 2006, International journal of cancer.

[30]  J. Folkman.  Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. , 2006, Experimental cell research.

[31]  N. Kyprianou,et al.  Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting , 2006, British journal of pharmacology.

[32]  J. Campisi.  Senescent Cells, Tumor Suppression, and Organismal Aging: Good Citizens, Bad Neighbors , 2005, Cell.

[33]  M. Ittmann,et al.  The role of fibroblast growth factors and their receptors in prostate cancer. , 2004, Endocrine-related cancer.

[34]  Philip Hahnfeldt,et al.  Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. , 2003, Cancer research.

[35]  W. Figg,et al.  The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. , 2003, Clinical prostate cancer.

[36]  H. Klocker,et al.  Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia , 2003, The Prostate.

[37]  Leif E. Peterson,et al.  Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. , 2003, Cancer research.

[38]  T. Veenstra,et al.  Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. , 2003, Molecular cancer therapeutics.

[39]  N. Greenberg,et al.  SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. , 2003, Molecular cancer therapeutics.

[40]  R. Cheng,et al.  Age-Associated Changes in Histology and Gene-Expression Profile in the Rat Ventral Prostate , 2003, Laboratory Investigation.

[41]  L. Matrisian,et al.  Matrix metalloproteinases in tumor-host cell communication. , 2002, Differentiation; research in biological diversity.

[42]  E. Voest,et al.  Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches , 2002, Molecular and Cellular Endocrinology.

[43]  J. Campisi,et al.  Cancer and aging: a model for the cancer promoting effects of the aging stroma. , 2002, The international journal of biochemistry & cell biology.

[44]  J. Tuxhorn,et al.  Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. , 2002, Cancer research.

[45]  G. Ayala,et al.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  W. Figg,et al.  Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer , 2002, Investigational New Drugs.

[47]  J. Fracchia,et al.  Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. , 2002, The Journal of urology.

[48]  N. Bouck,et al.  Thrombospondin‐1, vascular endothelial growth factor and fibroblast growth factor‐2 are key functional regulators of angiogenesis in the prostate , 2001, The Prostate.

[49]  G. Ayala,et al.  Reactive stroma in prostate cancer progression. , 2001, The Journal of urology.

[50]  T. Brown,et al.  Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate. , 2001, Endocrinology.

[51]  Luiz Paulo Fávero,et al.  Design and Analysis of Experiments , 2001, Handbook of statistics.

[52]  J. Simons,et al.  Angiogenesis and prostate cancer: identification of a molecular progression switch. , 2001, Cancer research.

[53]  E. De Clercq,et al.  Angiogenesis: regulators and clinical applications. , 2001, Biochemical pharmacology.

[54]  K. Nakasho,et al.  Inhibition by an angiogenesis inhibitor, TNP-470, of the growth of a human hepatoblastoma heterotransplanted into nude mice. , 2000, Journal of pediatric surgery.

[55]  J. Au,et al.  Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Slater,et al.  Changes in Growth Factor Expression in the Ageing Prostate may Disrupt Epithelial–Stromal Homeostasis , 2000, The Histochemical Journal.

[57]  S. Foley,et al.  Microvessel density in prostatic hyperplasia , 2000, BJU international.

[58]  K. Biemann,et al.  Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. , 1999, Chemistry & biology.

[59]  B. Foster,et al.  Pathologic progression of autochthonous prostate cancer in the TRAMP model , 1999, Prostate Cancer and Prostatic Diseases.

[60]  C. Logothetis,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0253 , 2022 .

[61]  J. Isner,et al.  Age-dependent impairment of angiogenesis. , 1999, Circulation.

[62]  B. Zirkin,et al.  Age-dependent and lobe-specific spontaneous hyperplasia in the brown Norway rat prostate. , 1998, Biology of reproduction.

[63]  Daniel B. Rifkin,et al.  Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis , 1998, The Journal of cell biology.

[64]  P. Puchner,et al.  Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. , 1998, Urology.

[65]  J. Nelson,et al.  Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[67]  H. Yoshiji,et al.  Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. , 1997, Cancer research.

[68]  W. Bornmann,et al.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[69]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[70]  V. Castronovo,et al.  TNP-470 (AGM-1470): mechanisms of action and early clinical development. , 1996, European journal of cancer.

[71]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[72]  W. Zhou,et al.  A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. , 1994, Cancer research.

[73]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[74]  J. Richie,et al.  Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. , 1993, The Journal of urology.

[75]  W. Ershler.  Why tumors grow more slowly in old people. , 1986, Journal of the National Cancer Institute.

[76]  Christina K. Chan,et al.  Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation , 2014, In Vitro Cellular & Developmental Biology - Animal.

[77]  P. Dijke,et al.  Regulation of endothelial cell plasticity by TGF-β , 2011, Cell and Tissue Research.

[78]  N. MacDonald,et al.  Angiostatin and Endostatin: Endogenous Inhibitors of Tumor Growth , 2004, Cancer and Metastasis Reviews.

[79]  G. Semenza,et al.  Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. , 2004, Cancer detection and prevention.

[80]  B. Foster,et al.  Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression , 2003, The Prostate.

[81]  T. Brown,et al.  Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age. , 2000, Endocrinology.

[82]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[83]  P. Hahnfeldt,et al.  19 The Logic of Anti-angiogenic Gene Therapy , 1999 .

[84]  A. Bergh,et al.  Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. , 1998, Endocrinology.

[85]  B. Zetter,et al.  Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. , 1996, Growth factors.